PIRAMAL PHARMA
Quarterly Results Analysis [Mar2025]
PIRAMAL PHARMA Quarterly Results
Consolidated | Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹2,754 Cr | ₹2,204 Cr | ₹2,242 Cr | ₹1,951 Cr | ₹2,552 Cr | ₹1,959 Cr | ₹1,911 Cr | ₹1,749 Cr |
Expenses | ₹2,193 Cr | ₹1,866 Cr | ₹1,900 Cr | ₹1,747 Cr | ₹2,022 Cr | ₹1,690 Cr | ₹1,646 Cr | ₹1,617 Cr |
Operating Income | ₹561 Cr | ₹338 Cr | ₹342 Cr | ₹204 Cr | ₹530 Cr | ₹268 Cr | ₹266 Cr | ₹132 Cr |
Other Income | ₹42 Cr | ₹12 Cr | ₹61 Cr | ₹20 Cr | ₹26 Cr | ₹62 Cr | ₹49 Cr | ₹38 Cr |
Interest | ₹104 Cr | ₹103 Cr | ₹108 Cr | ₹107 Cr | ₹114 Cr | ₹106 Cr | ₹110 Cr | ₹119 Cr |
Depreciation | ₹243 Cr | ₹197 Cr | ₹192 Cr | ₹185 Cr | ₹196 Cr | ₹186 Cr | ₹185 Cr | ₹174 Cr |
Profit Before Tax | ₹257 Cr | ₹50 Cr | ₹103 Cr | ₹-67 Cr | ₹215 Cr | ₹5 Cr | ₹20 Cr | ₹-122 Cr |
Profit After Tax | ₹137 Cr | ₹-13 Cr | ₹5 Cr | ₹-111 Cr | ₹89 Cr | ₹-4 Cr | ₹-14 Cr | ₹-113 Cr |
EPS | ₹1.16 | ₹0.03 | ₹0.17 | ₹-0.67 | ₹0.77 | ₹0.08 | ₹0.04 | ₹-0.81 |
Industry Peers & Returns | 1W | 1M | 1Y |
PIRAMAL PHARMA | 1.1% | -2.7% | 37.6% |
SUN PHARMACEUTICAL INDUSTRIES | -0.5% | -8.4% | 14.6% |
DIVIS LABORATORIES | -2.4% | 7.2% | 50.6% |
CIPLA | -0.7% | -3.7% | -1% |
TORRENT PHARMACEUTICALS | -1.4% | -3.9% | 19% |
DR REDDYS LABORATORIES | 0.5% | 5.6% | 5.1% |
MANKIND PHARMA | -1.6% | 1.3% | 17% |
ZYDUS LIFESCIENCES | 1.2% | 4.9% | -11.5% |
LUPIN | -0.5% | -4.8% | 22.1% |
PIRAMAL PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 24.95 % |
Y-o-Y | 7.90 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹2,754 Cr | 24.95 | |
Dec2024 | ₹2,204 Cr | -1.67 | |
Sep2024 | ₹2,242 Cr | 14.89 | |
Jun2024 | ₹1,951 Cr | -23.56 | |
Mar2024 | ₹2,552 Cr | 30.32 | |
Dec2023 | ₹1,959 Cr | 2.47 | |
Sep2023 | ₹1,911 Cr | 9.29 | |
Jun2023 | ₹1,749 Cr | - |
PIRAMAL PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 66.10 % |
Y-o-Y | 5.86 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹561 Cr | 66.10 | |
Dec2024 | ₹338 Cr | -1.13 | |
Sep2024 | ₹342 Cr | 67.05 | |
Jun2024 | ₹204 Cr | -61.41 | |
Mar2024 | ₹530 Cr | 97.46 | |
Dec2023 | ₹268 Cr | 1.03 | |
Sep2023 | ₹266 Cr | 100.76 | |
Jun2023 | ₹132 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 32.96 % |
Y-o-Y | -1.88 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 20.37% | 32.96 | |
Dec2024 | 15.32% | 0.52 | |
Sep2024 | 15.24% | 45.42 | |
Jun2024 | 10.48% | -49.52 | |
Mar2024 | 20.76% | 51.53 | |
Dec2023 | 13.7% | -1.44 | |
Sep2023 | 13.9% | 83.62 | |
Jun2023 | 7.57% | - |
PIRAMAL PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | Positive |
Y-o-Y | 53.85 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹137 Cr | Positive | |
Dec2024 | ₹-13 Cr | Negative | |
Sep2024 | ₹5 Cr | Positive | |
Jun2024 | ₹-111 Cr | Negative | |
Mar2024 | ₹89 Cr | Positive | |
Dec2023 | ₹-4 Cr | Negative | |
Sep2023 | ₹-14 Cr | Negative | |
Jun2023 | ₹-113 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | Positive |
Y-o-Y | 42.29 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 4.98 % | Positive | |
Dec2024 | -0.61 % | Negative | |
Sep2024 | 0.24 % | Positive | |
Jun2024 | -5.69 % | Negative | |
Mar2024 | 3.5 % | Positive | |
Dec2023 | -0.2 % | Negative | |
Sep2023 | -0.74 % | Negative | |
Jun2023 | -6.46 % | - |
PIRAMAL PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 3,766.67 % |
Y-o-Y | 50.65 % |
Quarters | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹1.16 | 3,766.67 | |
Dec2024 | ₹0.03 | -82.35 | |
Sep2024 | ₹0.17 | Positive | |
Jun2024 | ₹-0.67 | Negative | |
Mar2024 | ₹0.77 | 862.50 | |
Dec2023 | ₹0.08 | 100.00 | |
Sep2023 | ₹0.04 | Positive | |
Jun2023 | ₹-0.81 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD